exv10w59



 





[Execution Copy]




COLLABORATION AGREEMENT




BETWEEN




MARTEK BIOSCIENCES CORPORATION




AND




SEMBIOSYS GENETICS, INC.




December 1, 2003




 









 








COLLABORATION AGREEMENT




     This COLLABORATION AGREEMENT (the “Agreement”) is entered into as of
December 1, 2003 by and between MARTEK BIOSCIENCES CORPORATION (“MARTEK”), a
Delaware corporation having its registered office at 6480 Dobbin Road,
Columbia, MD 21045, USA, and SEMBIOSYS GENETICS, INC. (“SEMBIOSYS”), a Canadian
corporation, having its registered office at 110, 2985 – 23 Avenue N.W.,
Calgary, AB, T1Y 7L3, CANADA.



     WHEREAS, MARTEK has expertise in the discovery and use of synthesis genes
which are embodied in MARTEK’s proprietary polyketide synthase (“PKS”)
technology to manufacture certain long-chain polyunsaturated fatty acids
(“LC-PUFAs”); and



     WHEREAS, SEMBIOSYS has expertise in the expression of transgenes in crop
species; and



     WHEREAS, MARTEK and SEMBIOSYS wish to enter into this Agreement in order
to collaborate in the development of transgenic plants useful in producing
LC-PUFAs of interest to MARTEK; and



     WHEREAS, SEMBIOSYS will perform work which will be funded and supported by
MARTEK in order to develop such transgenic plants and will license the results
of such efforts to MARTEK in the Territory for the purpose of the production,
manufacture and sale of products in the Field (as hereinafter defined).



     NOW, THEREFORE, in consideration of the mutual covenants contained herein,
and for other good and valuable consideration, the parties hereby agree as
follows:



1. DEFINITIONS




     Whenever used in this Agreement with an initial capital letter, the terms
defined in this Section 1 shall have the meanings specified.



*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission



2









 








     1.1 “Affiliate” means any corporation, firm, limited liability company,
partnership or other entity which directly or indirectly controls or is
controlled by or is under common control with a party to this Agreement. For
purposes of this definition, “Control” means ownership, directly or through one
or more Affiliates, of more than fifty percent (50%) of the shares of stock
entitled to vote for the election of directors, in the case of a corporation,
or more than fifty percent (50%) of the equity interests in the case of any
other type of legal entity, status as a general partner in any partnership, or
any other arrangement whereby a party controls or has the right to control the
Board of Directors or equivalent governing body of a corporation or other
entity.



     1.2 “ARA” means arachidonic acid.



     1.3 “Calendar Quarter” means one quarter of a Calendar Year.



     1.4 “Calendar Year” means the twelve month period beginning January 1 and
ending December 31.



     1.5 “Change of Control” shall mean any of the following: (a) the
acquisition in a transaction or series of transactions by any Person (such term
to include anyone deemed a person under Section 13(d)(3) under the Exchange
Act), of beneficial ownership (within the meaning of Rule 13d-3 promulgated
under the Exchange Act) of 50% (fifty percent) per annum or more of the
combined voting power of the then-outstanding voting securities of SEMBIOSYS
entitled to vote generally in the election of directors; or (b) the sale or
other disposition of all or substantially all of the assets of SEMBIOSYS to
which this Agreement relates in one transaction or series of related
transactions.



     1.6 “Confidential Information” means all information and proprietary
materials (including but not limited to information about any element of
Program Know-How) which are developed in the course of performance of the R&D
Program or disclosed by one party to the other hereunder or under the
Superseded Confidentiality Agreement (as defined in Section



*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission



3









 








13.13) except to
the extent that any such information or material (i) as of the date of
disclosure is demonstrably known to or in the possession of the party receiving
such disclosure or its Affiliates, as shown by written documentation, other
than by virtue of a prior confidential disclosure from the other party to such
party or its Affiliates; (ii) as of the date of disclosure is in, or
subsequently enters, the public domain, through no fault or omission of the
party receiving such disclosure; or (iii) as of the date of disclosure or
thereafter is rightfully obtained from a Third Party free from any obligation
of confidentiality.



     1.7 “Control” or “Controlled” means, with respect to rights in
intellectual property, the possession by a party of the ability to grant a
license or sublicense of such rights without the payment of additional
consideration and/or without violating the terms of any agreement or
arrangement between such party and any Third Party.



     1.8 “DHA” means docosahexaenoic acid.



     1.9 “Effective Date” means December 1, 2003.



     1.10 “EPA” means eicosapentaenoic acid.



     1.11 “Field” means the production, manufacture and marketing of DHA,
ARA and EPA produced in transgenic plants.



     1.12 “FTE” means the equivalent of a full year of effort on a full time
basis (approximately 2,000 hours) of a scientist or other professional
possessing skills and experience
necessary to carry out the R&D Program, determined in accordance with
SEMBIOSYS’ normal policies and procedures.



     1.13 “Gross Margin” means, with respect to Licensed Products, sales
revenue less the cost of goods sold as determined in accordance with Exhibit
B attached hereto.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission



4









 





     1.14 “Invention” shall mean any new and useful process, manufacture or
composition of matter which is conceived and first reduced to practice,
constructively or actually, in the course of performance of the R&D Program.
“SEMBIOSYS Inventions” shall mean Inventions conceived and first reduced to
practice solely by employees of SEMBIOSYS. “MARTEK Inventions” shall mean
Inventions conceived and first reduced to practice solely by employees of
MARTEK. “Joint Inventions” shall mean Inventions conceived and first reduced
to practice jointly by employees of MARTEK and SEMBIOSYS.



     1.15 A party or a party’s employees will be deemed to have made an
“Inventive Contribution” to a patentable invention or copyrightable work if
such employee would be considered an inventor or author under 35 U.S.C. et.
seq. or 17 U.S.C. et. seq., and as interpreted by the U.S. Patent and Trademark
Office and the U.S. Copyright Office, respectively, and the United States
courts.



     1.16 An item will be considered “Jointly” developed or invented by both
parties if employees of both parties made an Inventive Contribution to the
invention or development thereof.



     1.17 “License Term” means the time period referenced in Section 8.2.



     1.18 “Licensed Product” means any product or any part thereof, that (i)
the production, manufacture, use or sale of which would infringe any Valid
Claim contained in any patent rights licensed to MARTEK by SEMBIOSYS hereunder,
or (ii) which is produced
through the direct and material use of SEMBIOSYS Program Know-How or Joint
Program Know-How.



     1.19 “MARTEK Background Technology” means proprietary technology,
materials and/or information, including without limitation, patents and patent
applications, owned or Controlled by MARTEK as of the Effective Date or
developed outside of the R&D Program


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission



5









 





during the Term hereof and useful in the
Field and which MARTEK has the right to use in the Field.



     1.20 “MARTEK Improvements” means (a) Inventions which claim the
identification, composition or use (i) of DHA, EPA and/or ARA synthesis genes
or (ii) of supplemental genes used or evaluated in the course of performance of
the R&D Program for enhancing DHA, EPA or ARA production in plants, and (b) all
Program Know-How other than Inventions that is directly related to (a) above.



     1.21 “Material Competitor” shall mean a Third Party which MARTEK
reasonably believes to be a material competitor of MARTEK in the DHA
marketplace and/or the Field.



     1.22 “Patent Coordinator” has the meaning set forth in Section 6.3



     1.23 “Patent Rights” means the rights and interests in and to issued
patents and pending patent applications in any country, including, but not
limited to, all provisional applications, substitutions, continuations,
continuations-in-part, divisions, and renewals, all letters patent granted
thereon, and all reissues, reexaminations and extensions thereof, whether owned
solely or jointly by a party, wherein at least one claim of such patent right
is directly based, in whole or in part, on an Invention. “SEMBIOSYS Patent
Rights” shall mean Patent Rights with respect to SEMBIOSYS Improvements and
with respect to SEMBIOSYS Inventions other than MARTEK Improvements. “MARTEK
Patent Rights” shall mean Patent Rights with respect to MARTEK Improvements and
with respect to MARTEK Inventions other than SEMBIOSYS Improvements. “Joint
Patent Rights” shall mean Patent Rights with respect to Joint Inventions which
are not MARTEK Improvements or SEMBIOSYS Improvements.



     1.24 “POC” means proof of concept as referenced in Section 2.1.1(a), and
as further defined in Exhibit A.



     1.25 “Program Intellectual Property” means all Patent Rights and Program
Know-How. “SEMBIOSYS Program Intellectual Property” shall mean SEMBIOSYS
Patent Rights


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission



6









 





and SEMBIOSYS Program Know-How. “MARTEK Program Intellectual
Property” shall mean MARTEK Patent Rights and MARTEK Program Know-How. “Joint
Program Intellectual Property” shall mean Joint Patent Rights and Joint Program
Know-How.



     1.26 “Program Know-How” means, without limitation, all Inventions and all
proprietary and non-patented inventions, improvements, discoveries, proprietary
materials, biological substances, data, know-how and all trade secrets, in each
case which are developed in the course of performance of the R&D Program.
“SEMBIOSYS Program Know-How” shall mean Program Know-How which is a SEMBIOSYS
Improvement or which is invented or developed solely by employees of SEMBIOSYS
and which is not a MARTEK Improvement. “MARTEK Program Know-How” shall mean
Program Know-How which is a MARTEK Improvement or which is invented or
developed solely by employees of MARTEK and which is not a SEMBIOSYS
Improvement. “Joint Program Know-How” shall mean Program Know-How invented or
developed Jointly by employees of both parties and which is not a MARTEK
Improvement or a SEMBIOSYS Improvement.



     1.27 “R&D Program” means the research and development program to be
conducted by SEMBIOSYS and MARTEK pursuant to Section 2 and which is described
in the Workplans.



     1.28 “Research Steering Committee” or “RSC” means the committee created
pursuant to Section 2.2 hereof.



     1.29 “Research Term” has the meaning set forth in Section 2.3.1.



     1.30 “SEMBIOSYS Background Technology” means proprietary technology,
materials and/or information, including without limitation patents and patent
applications, owned or Controlled by SEMBIOSYS as of the Effective Date or
developed or acquired outside of the R&D Program during the Term hereof and
useful in the Field and which SEMBIOSYS has the right to use in the Field.
SEMBIOSYS Background Technology shall expressly exclude, for purposes of this
Agreement, any rights of SEMBIOSYS under any Third Party License.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission



7









 





     1.31 “SEMBIOSYS Improvements” means (a) Inventions which claim (i) methods
of transforming genes or expressing genes in plants or (ii) methods of making
or using plant oil bodies, and (b) all Program Know-How other than Inventions
that is directly-related to (a) above.



     1.32 “Term” has the meaning set forth in Section 9.1.



     1.33 “Territory” means all the countries of the world.



     1.34 “Third Party” shall mean any party who is not a party hereto, or an
Affiliate, licensee or sublicensee thereof.



     1.35 “Third Party License” has the meaning set forth in Section 10.2.1.



     1.36 “Valid Claim” means (i) a claim of a pending patent application, or
(ii) an issued, unexpired patent claim which has not been held unenforceable,
unpatentable or invalid by a decision of a court or other governmental agency
of competent jurisdiction, unappealed within the time allowed for appeal or
unappealable, and which claim has not been admitted to be invalid or
unenforceable through reissue, reexamination, disclaimer or otherwise.



     1.37 “Workplan” means the written plan describing the activities to be
carried out in the course of performance of the R&D Program.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission



8









 





2. R&D PROGRAM




     2.1 Implementation of R&D Program.



     2.1.1 Basic Provisions of Program.



          (a) The objectives of the R&D Program, as further described in Exhibit
A attached hereto, shall be to successfully complete the following phases
(each, a “Phase”): I) establish POC in * for the production of DHA using
MARTEK’s PKS technology, II) establish POC in commercial crop species *, III)
develop a commercial * cultivar, and IV) apply for and obtain regulatory
approvals for commercial crop cultivation, and generate sufficient DHA-rich
seed to support pre-commercialization studies for a plant-based DHA product and
achieve commercial approval.



          (b) SEMBIOSYS and MARTEK shall each use commercially reasonable efforts to
perform such tasks as are set forth to be performed by it in the relevant
Workplan. In carrying out the R&D Program, SEMBIOSYS shall devote such number
of FTEs as well as such other scientific resources (facilities, equipment, and
materials) as are necessary to perform the R&D Program as set forth in the
relevant Workplan or as otherwise agreed to by the parties and approved by
MARTEK for any given research period in accordance with the terms hereof.



          (c) In the course of performance of the R&D Program, MARTEK shall be
primarily responsible for carrying out that portion of the R&D Program that
involves supplying enabling PKS technology, which may include certain
technology improvements as needed (e.g., *, and MARTEK shall also be
responsible for processing and lipid analysis of oil from transgenic plant
tissue and seed. SEMBIOSYS shall be primarily responsible for carrying out, at
the direction of MARTEK, that portion of the R&D Program involving expressing
DHA PKS genes in plants, providing access to specialty crop germplasm and other
technology required to complete the R&D Program (e.g., transformation
technology for model and commercial hybrid crops), conducting field trials,
applying for and obtaining regulatory approvals for commercial


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission



9









 





crop cultivation, and establishing an identity preservation supply chain.
SEMBIOSYS and MARTEK will each provide to the other any information, materials
and technology possessed by each such party that is reasonably necessary to
achieve such party’s objectives under the R&D Program.



     2.1.2 Collaborative Efforts and Reports.



          (d) The parties agree that the successful execution of the R&D Program
will require the collaborative use of both parties’ areas of expertise. The
parties shall keep the RSC fully informed about the status of the portions of
the R&D Program they respectively perform. In particular, without limitation,
SEMBIOSYS shall furnish to the RSC quarterly written reports within thirty (30)
days after the end of each Calendar Quarter, describing the progress of its
activities in reasonable detail, including a description of Program
Intellectual Property arising from SEMBIOSYS’ research efforts and
accomplishments.



          (e) Scientists at SEMBIOSYS and MARTEK shall cooperate in the performance
of the R&D Program and, subject to any confidentiality obligations to third
parties, shall exchange information and materials as necessary to carry out the
R&D Program, subject to the provisions of Section 5. Each party will attempt
to accommodate any reasonable request of the other party to send or receive
personnel for purposes of collaborating or exchanging information under the R&D
Program. Such visits and/or access will have defined purposes and be scheduled
in advance.



     2.1.3 Workplans.



          (a) An overall Workplan for the R&D Program is attached hereto as
Exhibit A, which Workplan also includes a detailed Workplan for at least
the first twelve (12) months of the R&D Program. At the end of each Calendar
Quarter, a detailed Workplan for the next twelve (12) months shall be prepared
by SEMBIOSYS and MARTEK and approved in writing by MARTEK, no later than ten
(10) days after the end of such Calendar
Quarter. The detailed


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission



10









 





Workplans for each twelve (12) month period shall set
forth specific research and development objectives, milestones and resource
allocation requirements and shall be designed to facilitate the earliest
practical achievement of the objectives of the R&D Program. Each Workplan,
including the overall Workplan and the detailed twelve-month Workplan, shall be
in writing and shall set forth with reasonable specificity tasks for the period
covered by the Workplan. The RSC may make adjustments in the Workplan as it may
determine, subject to MARTEK’s written approval.



          (b) Notwithstanding anything to the contrary in this Agreement, in no
event shall MARTEK have the right to unilaterally reduce the projected time
required for completion of any Phase of the Workplan or to unilaterally expand
the scope of the work required pursuant to the Workplan for the primary purpose
of preventing SEMBIOSYS from becoming eligible for any Milestone Payment due
pursuant to Section 4.3. Notwithstanding the above, MARTEK shall not expand
any phase of the Workplan unless such expansion is necessary, in MARTEK’s
reasonable judgment, to achieve the objectives of the R&D Program.



     2.1.4 Exclusivity.



          (a) SEMBIOSYS agrees that, during the Research Term and for a period of
one (1) year thereafter, SEMBIOSYS will not, itself or through another party,
perform research in the Field or collaborate in the performance of research in
the Field with any other commercial party and will not, itself or through
another party, undertake such activities for the benefit of any other
commercial party in the Field, except as otherwise permitted hereby.
Notwithstanding the foregoing, this Agreement shall not in any way restrict
SEMBIOSYS’ right to perform research or collaborate with Third Parties outside
of the Field and to grant to Third Parties the right to exploit the results of
any such research or collaborations outside the Field; provided, however, that
nothing in this Section 2.1.4(a) shall be deemed to affect the scope of any
licenses or rights expressly granted to MARTEK pursuant to Section 6.2 below or
the parties’ obligations with respect to Program Intellectual Property pursuant
to Section 5.1 below.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission



11









 





          (b) MARTEK agrees that MARTEK will not use and/or replicate any SEMBIOSYS
Background Technology or utilize any SEMBIOSYS Program Intellectual Property
for any purpose other than as provided herein. SEMBIOSYS agrees that SEMBIOSYS
will not use and/or replicate any MARTEK Background Technology or utilize any
MARTEK Program Intellectual Property for any purpose other than as provided
herein.



     2.2 Research Steering Committee.



     2.2.1 Establishment and Functions of RSC.



          (a) SEMBIOSYS and MARTEK shall establish an RSC. The RSC will act on
behalf of the two companies and will facilitate the planning and monitoring of
the R&D Program. In particular, the activities of the RSC shall include
reviewing progress in the R&D Program and recommending necessary adjustments to
the Workplans, including recommending any modifications deemed desirable based
on results as the research and development progresses.



          (b) In facilitating the planning and monitoring of the R&D Program, the
RSC shall, subject to MARTEK’s prior approval, assign tasks and
responsibilities taking into account each party’s respective specific
capabilities and expertise in order, in particular, to avoid duplication and
enhance efficiency and synergies.



     2.2.2 RSC Membership.



     SEMBIOSYS and MARTEK each shall appoint, in their sole discretion, two (2)
members to the RSC, which shall include a Project Manager to be designated by
each party. Substitutes or alternates of the RSC members may be appointed at
any time by notice in writing to the other party. The parties may mutually
agree to change the size of the RSC as long as there shall be an equal number
of representatives of each party on the RSC. The initial RSC members shall be


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission



12









 





designated by the parties upon execution of this Agreement. The SEMBIOSYS
Project Manager shall be reasonably satisfactory to MARTEK.



     2.2.3 Meetings.



     The RSC shall meet at least quarterly, with such meetings to be held,
alternately, in Calgary, Alberta for SEMBIOSYS, and either Columbia, Maryland
or Boulder, Colorado for MARTEK (at MARTEK’s election) unless the parties agree
otherwise. Any additional meetings shall be held at places and on dates
selected by the parties. In addition, the RSC may act via teleconference or
video-conference. Subject to the obligations set forth in Section 5,
representatives of each party or of its Affiliates, in addition to the members
of the RSC, may attend RSC meetings at the invitation of either party with the
prior approval of the other party, which shall not be unreasonably withheld.



     2.2.4 Minutes.



     The RSC shall keep accurate minutes of its deliberations which record all
proposed decisions and all actions recommended or taken. Drafts of the minutes
shall be delivered to the Project Managers within twenty (20) days after the
meeting. The party hosting the meeting shall be responsible for the preparation
and circulation of the draft minutes. Draft minutes shall be edited by the
Project Managers and shall be issued in final form only with their approval and
agreement as evidenced by their signatures on the minutes.



     2.2.5 Decisions.



     The objective of the parties to this Agreement is that decisions of the
RSC shall be made by consensus. However, except as otherwise set forth herein,
in the event that the RSC is unable


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission



13









 






to resolve any matter before it as set forth above, such matter shall be
resolved by MARTEK, taking into reasonable consideration the best interests of
both MARTEK and SEMBIOSYS.



     2.2.6 Expenses.



     SEMBIOSYS and MARTEK shall each bear all expenses of their respective RSC
members related to their participation on the RSC and attendance at RSC
meetings; provided, however, that FTE related expenses and reasonable out of
pocket travel costs of SEMBIOSYS RSC members in connection with the foregoing
shall be considered R&D Program expenses and shall be billed to MARTEK as
provided in Section 4.2.



     2.3 Research and Development Term.



     2.3.1 Term of the R&D Program.



     The initial term of the R&D Program shall expire three (3) years after the
Effective Date unless extended as provided in Section 2.3.2, or unless earlier
terminated by either party pursuant to the provisions in this Section 2.3
and/or Article 9 (the “Research Term”).



     2.3.2 Extension of the Research Term.



     Upon successful completion of the “First R&D Milestone” as set forth in
the Workplan attached hereto as Exhibit A, the Research Term shall be
extended for the duration of the second Phase (Phase II) based on the timeline
and milestones contained in the outline of the Workplan for Phase II as set
forth on Exhibit A attached hereto. Thereafter, upon written request of
MARTEK made prior to the expiration of any ongoing Phase of the R&D Program,
the Research Term shall be extended for the duration of the next subsequent
Phase of the R&D Program until such time as the R&D Program has been completed.



*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission



14









 





     2.3.3 Early Termination of the R&D Program.



          (a) MARTEK may terminate the R&D Program at its sole discretion upon
written notice to SEMBIOSYS if POC in a model plant is not demonstrated within
three (3) years of the Effective Date or such other date as is agreed by the
parties in writing.



          (b) MARTEK may terminate the R&D Program at its sole discretion upon six
(6) months prior written notice, provided, however, such notice may only
be given on or after the first anniversary of the Effective Date.



          (c) Either party may terminate the R&D Program on written notice to the
other party in the event that licenses to Third Party intellectual property
reasonably believed by such party to be necessary for the conduct of the R&D
Program cannot be obtained at reasonable cost by the relevant party as
described in Section 3.2 hereof. Such notice may only be given after
presentation to the RSC of the reasons that such Third Party intellectual
property is reasonably believed to be necessary for the conduct of the R&D
Program and discussion of the terms offered by such Third Party for a license
under such intellectual property, and after allowing at least sixty (60) days
for good faith discussions among the RSC members regarding the need for such
Third Party intellectual property and the available terms for licensing.



          (d) Any termination of the R&D Program under Section 2.3.3 shall also
result in termination of the Research Term and of this Agreement, subject to
the provisions of Article 9, and shall be without prejudice to the rights of
either party against the other, then accruing or otherwise accrued under this
Agreement. Further, upon any such termination, all remaining MARTEK Background
Technology provided to SEMBIOSYS under this Agreement shall be returned to
MARTEK or destroyed.



     2.3.4 Post Research Term Cooperation.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




15









 








     At least three months prior to any expiration or termination of the
Research Term pursuant to Section 2.3.3, the parties shall meet to agree on
mechanisms for coordinating and managing activities which shall occur after the
expiration of the Research Term which would otherwise be addressed by the RSC
hereunder including but not limited to (i) reporting on the development of
Inventions; (ii) decisions with respect to patent filing and prosecution; (iii)
resolution of inventorship disputes; and (iv) other items as needed.



3. ADDITIONAL PROGRAMS; THIRD PARTY LICENSES




     3.1 Right of First Negotiation for SEMBIOSYS.



     3.1.1 EPA and/or ARA Collaborations.



     In the event that at any time during the longer of the Research Term and
the ten (10) year term after termination of this Agreement during which the
confidentiality provisions under Section 5.1.1 below shall remain in effect,
MARTEK desires to collaborate with a Third Party in the development of
plant-based EPA and/or ARA, MARTEK shall notify SEMBIOSYS in writing, which
notice shall specify in reasonable detail the structure of the collaboration
desired by MARTEK (the “MARTEK Notice”). SEMBIOSYS shall have thirty (30) days
after receipt of any MARTEK Notice to provide a written response to MARTEK (the
“SEMBIOSYS Response”) as to whether or not it wishes to enter into negotiations
with MARTEK concerning the collaboration described in such MARTEK Notice. If
MARTEK does not receive a SEMBIOSYS Response within such thirty (30) day period
or if SEMBIOSYS declines to enter into negotiations, MARTEK shall thereafter
have the right to negotiate and enter into a collaboration with any Third Party
regarding the rights which were the subject of the MARTEK Notice, free of any
duty to SEMBIOSYS pursuant to this Section 3.1.1. If the SEMBIOSYS Response
states that SEMBIOSYS wishes to enter into negotiations with MARTEK, the
parties shall negotiate in good faith the terms of a mutually acceptable
collaboration agreement for a period of sixty (60) days from the date of the
SEMBIOSYS Response.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




16









 







     If the parties do not agree upon and execute a written agreement for such
collaboration within such sixty (60) day period, as such period may be extended
by written agreement of both parties, SEMBIOSYS shall set forth in writing in
detail its “last best offer” with respect to such collaboration. If MARTEK
does not accept such last best offer, MARTEK will furnish SEMBIOSYS with a
written statement that it rejects such last best offer, and MARTEK shall
thereafter have the right, for a period of two (2) years thereafter, to pursue
a collaboration with a Third Party regarding the subject of the MARTEK Notice,
but only on terms reasonably believed by MARTEK to be more favorable in the
aggregate to MARTEK than SEMBIOSYS’ last best offer. After the expiration of
such two-year period, if no agreement is reached with any Third Party with
respect to the subject matter of the relevant MARTEK Notice, SEMBIOSYS shall
again have a right of first negotiation pursuant to this Section 3.1.1.




     3.1.2 Personal Care Applications. In the event that MARTEK intends
to offer exclusive rights to use or sell Licensed Products in the Field to any
Third Party in any geographic region for personal care applications, MARTEK
will first notify SEMBIOSYS and SEMBIOSYS shall have a right of first
negotiation with respect to any such exclusive rights on terms substantially
similar to those described in Section 3.1.1 above.



     3.2 Third Party Intellectual Property.



     In the event that any license to any intellectual property owned by third
parties is reasonably believed by the parties to be required for the
performance of the R&D Program and/or the commercialization of any resulting
products in the Field, unless otherwise agreed by the parties, (a) MARTEK shall
be responsible for using commercially reasonable efforts to obtain at its
expense any licenses relating to the use of the PKS technology and/or the DHA
synthesis genes, (b) SEMBIOSYS shall be responsible for using commercially
reasonable efforts to obtain at its expense any licenses relating to the
development and commercialization of transgenic plants in general, and (c) the
parties shall agree in good faith on a case-by-case basis


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




17









 







on who shall be responsible for obtaining and bearing the cost of any licenses
to any other technology that is required.




4. R&D PROGRAM FUNDING




     4.1 Budget.



     The initial budget for the combined direct costs and milestone payments
for the R&D Program are detailed in Exhibit A. Such budget may be
modified from time to time subject to MARTEK’s prior written approval. MARTEK
shall not be responsible for any expenditures in excess of any such approved
budget without MARTEK’s prior written approval. All payments to be made to
SEMBIOSYS pursuant to this Article 4 shall be paid to SEMBIOSYS in Canadian
dollars.



     4.2 Payments.



     In consideration of the work to be done by SEMBIOSYS in the performance of
the R&D Program, MARTEK will pay SEMBIOSYS * per FTE’s worth of effort devoted
to the R&D Program during the Research Term, plus approved out-of-pocket
expenses as indicated in the relevant approved budget. MARTEK will fund its
own activities under the R&D Program.



     Upon execution of this Agreement, MARTEK shall advance to SEMBIOSYS
US$500,000 as prepaid R&D Program funding. At the end of each month, SEMBIOSYS
shall submit monthly itemized invoices of actual R&D Program expenses to
MARTEK, which MARTEK shall pay within 30 days of receipt. Upon any termination
of this Agreement within the first year following the Effective Date, SEMBIOSYS
shall return * of such prepaid amount to MARTEK (* if termination is due to
breach by SEMBIOSYS). Thereafter, upon any termination other than due to
breach by SEMBIOSYS, SEMBIOSYS shall be entitled to retain the entire
prepayment. Notwithstanding the foregoing, MARTEK shall be entitled to offset
any


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




18









 







such retained prepayment against any final monthly invoice received from
SEMBIOSYS at a rate of exchange equal to 1.0Cdn$ = 0.7336US$.




     4.3 Milestone Payments.



          (a) MARTEK shall also make milestone payments to SEMBIOSYS as provided in
(c) below at the end of each of Phases I – IV of the R&D Program completed by
SEMBIOSYS hereunder contingent upon the successful achievement of each of (I)
meeting or exceeding the relevant milestone for such Phase of the R&D Program
as set forth in Exhibit A, (II) meeting or beating the timeframes
specified in Exhibit A for completing such Phase of the R&D Program
based on time elapsed since the date of actual receipt by SEMBIOSYS of the last
of the initial set of resynthesized DHA synthesis genes to be provided by
MARTEK upon commencement of the R&D Program, which date is anticipated to be no
later than January 1, 2004, and which date shall be confirmed in writing by the
parties promptly following its occurrence and which shall be subject to further
adjustment as provided in (b) below), and (III) completing such Phase of the
R&D Program for under the agreed upon Budget Cap as specified in Exhibit
A.



          (b) The specified completion date for each Phase (Ia-IV) of the R&D
Program shall be adjusted, for purposes of this Section 4.3 only, by adding
time for delays incurred in achieving successful completion of any prior Phases
to the timeframe specified in Exhibit A plus a grace period of up to one
hundred and eighty (180) days; provided, however, that (i) in no event shall
any such adjustment result in a specified completion date for any relevant
Phase of the R&D Program being adjusted to a date that is later than the
following number of days after the completion date for such Phase as specified
in Exhibit A: the sum of (A) one hundred and eighty (180) days, plus
(B) the time for delays actually incurred in achieving successful completion of
any prior Phases; and provided further, that (ii) in no event shall any such
adjustment result in a specified completion date for any Phase which is more
than eighteen (18) months from the completion date for such Phase as specified
in Exhibit A.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




19









 








          (c) Notwithstanding the foregoing Section 4.3(b), any delays that are
caused by MARTEK through the lack of timely performance of any of its
obligations under the Workplan shall result in the specified completion dates
being adjusted as needed to not penalize SEMBIOSYS for any such MARTEK delay.



          (d) In the event that any Phase (I – IV) of the R&D Program is
successfully completed and is completed both on time and under budget, MARTEK
shall pay to SEMBIOSYS a milestone payment that is equivalent to one hundred
percent (100%) of the specified Budget Cap for such Phase less total expenses
billed to MARTEK for such Phase pursuant to Section 4.2, provided, however, all
such milestone payments, if any, shall be separately accounted for by SEMBIOSYS
and shall be kept reasonably available to be used by SEMBIOSYS to fund any
budget overruns in future Phases of the R&D Program, and provided further that
no additional milestone payments shall be available once total expended and/or
budgeted funds for the R&D Program (including updated budgets for remaining
Phases) have reached a total of *.



          (e) In addition to the provisions of subsection (d) above, the parties
agree as follows: In the event that the parties agree to continue with Phase
Ib of the R&D Program despite lack of successful completion of Phase Ia of the
R&D Program, then upon the successful completion of Phase Ib of the R&D Program
both on time and under budget, any milestone payment that is due to SEMBIOSYS
for the successful completion of Phase Ib shall be equal to the combined Budget
Caps less the expenditures billed by SEMBIOSYS for Phase Ia and Phase Ib of the
R&D Program. Further, in the event that Phase Ia of the R&D Program is
successful and the parties agree to not engage in the work described for Phase
Ib, then any milestone payment that is due to SEMBIOSYS for the successful
completion of Phase Ia both on time and under budget shall be equal to the
combined Budget Caps less the expenditures billed by SEMBIOSYS for Phase Ia and
Phase Ib of the R&D Program.



     4.4 Other Funding.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




20









 








     SEMBIOSYS will also assist MARTEK, upon request of MARTEK, in obtaining
economic incentives from the Canadian government related to the R&D Program and
if such incentives are actually received by MARTEK, MARTEK shall pay SEMBIOSYS
ten percent (10%) of any such incentive payments actually received.



5. TREATMENT OF CONFIDENTIAL INFORMATION




     5.1 Confidentiality.



     5.1.1 General.



     SEMBIOSYS and MARTEK each recognize that the other party’s Confidential
Information constitutes highly valuable and proprietary confidential
information. For the purposes hereof, (a) all MARTEK Background Technology
shall be deemed MARTEK Confidential Information; (b) all SEMBIOSYS Background
Technology shall be deemed SEMBIOSYS Confidential Information; and (c) subject
to each party’s compliance with its respective obligations under Articles 8 and
9, (i) all MARTEK Program Intellectual Property, all Joint Program Intellectual
Property which is directly related to the Field and/or SEMBIOSYS Program
Intellectual Property which is directly related to the Field shall be deemed
MARTEK Confidential Information, and (ii) all SEMBIOSYS Program Intellectual
Property not directly related to the Field shall be deemed SEMBIOSYS
Confidential Information. Subject to the terms and conditions of Articles 8
and 9, SEMBIOSYS and MARTEK each agree that, except as required by applicable
law or regulation (including the filing and prosecution of patent applications)
or judicial or administrative order, during the term of this Agreement and for
ten (10) years thereafter (or, with respect to information described in (a),
(b) and (c) above, in perpetuity); (x) it will keep confidential, and will
cause its employees, consultants, Affiliates, licensees and sublicensees to
keep confidential, all Confidential Information of the other party that is
disclosed to it, or to any of its employees, consultants, Affiliates and
licensees and sublicensees, pursuant to or in connection with this Agreement;
and (y) neither it nor any of its respective employees, consultants, Affiliates
and licensees and sublicensees shall use or disclose


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




21









 







Confidential Information of the other party for any purpose whatsoever
except as expressly permitted in this Agreement. Notwithstanding the
foregoing, (I) either party may disclose Confidential Information to its
permitted sublicensees as long as such sublicensees execute a confidentiality
agreement providing protections similar to those contained herein, and (II)
MARTEK will reasonably cooperate with SEMBIOSYS in the making of reasonable
disclosures of Confidential Information to investment bankers, investors and
potential investors of SEMBIOSYS; provided, however, that such disclosures
shall only be made under the terms of a confidentiality agreement providing
protections similar to those contained herein unless otherwise agreed in
writing by MARTEK.




     5.1.2 Restricted Access.



     SEMBIOSYS and MARTEK each agree that any disclosure of the other party’s
Confidential Information to any of its officers, employees, consultants or
agents or those of any of its Affiliates and licensees and sublicensees shall
be made only if and to the extent necessary to carry out its rights and
responsibilities under this Agreement, and shall be limited to the maximum
extent possible consistent with such rights and responsibilities. Each party,
upon the other’s request, will return all the Confidential Information
disclosed to it by the other party pursuant to this Agreement, including all
copies and extracts of documents, within sixty (60) days of the request of the
disclosing party following the expiration or termination of this Agreement;
provided that a party may retain Confidential Information of the other party
relating to any license or right which survives such termination and one copy
of all other Confidential Information may be retained in confidential and
inactive archives solely for the purpose of establishing the contents thereof.



     5.1.3 Employee Confidentiality and Invention Agreements.



     SEMBIOSYS and MARTEK each represent that all of its employees and all of
the employees of its Affiliates, and any consultants to such party or its
Affiliates, participating in the R&D Program or who shall otherwise have access
to Confidential Information of the other party


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




22









 







hereunder are bound by written agreements to assign rights in Inventions to
such party and to maintain any such information in confidence and to not use
such information except as expressly permitted herein. Each party agrees to
enforce confidentiality obligations to which its employees and consultants (and
those of its Affiliates) are obligated.




     5.2 Publicity.



     Neither party may disclose the existence or terms of this Agreement
without the prior written consent of the other party; provided, however, that
either party may make such a disclosure to the extent required by law and that
SEMBIOSYS may make a disclosure of the existence and terms of this Agreement to
investors, prospective investors, lenders and other financing sources;
provided, however, that such disclosures shall only be made under the terms of
a confidentiality agreement providing protections similar to those contained
herein. The parties, upon the execution of this Agreement, will agree to a
news release for publication in general circulation periodicals and news wires.
Once any written statement is approved for disclosure by both parties, either
party may make subsequent public disclosures limited to the specific contents
of such prior statement without the further approval of the other party.



     5.3 Publication.



     Any party wishing to publish or otherwise publicly disclose the results of
its research hereunder shall first submit a draft of the proposed manuscript to
the RSC and the Patent Coordinators (as defined in Section 6.3) for review,
comment and consideration of appropriate patent action at least thirty (30)
days prior to any submission for publication or other public disclosure. The
RSC will advise the party seeking publication as to whether publication will be
permitted and whether a patent application will be prepared and filed or
whether trade secret protection should be pursued, and the RSC will, in
cooperation with both parties, determine the appropriate timing and content of
any such permitted publications.



     5.4 Consultants.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




23









 








     Prior to retaining any consultant who shall have access to any
Confidential Information of the other party or who shall participate in the
performance of the R&D Program, each party shall use reasonable efforts to
determine if such consultant has or will have any potential conflict of
interest with respect to the other party as a result of any other relationships
of such consultant and will not retain any consultant known to have such a
conflict without the consent of the other party, such consent to not be
unreasonably withheld.



6. INTELLECTUAL PROPERTY RIGHTS




     6.1 Disclosure of Inventions.



     Each party shall promptly inform the other and the RSC about all
Inventions and other material Program Know-How developed hereunder. The
following provisions shall apply to rights in Program Intellectual Property.



     6.2 Ownership.



     6.2.1 SEMBIOSYS Intellectual Property Rights.



     Subject only to the rights and obligations expressly provided in this
Agreement, SEMBIOSYS shall have sole and exclusive ownership of all right,
title and interest on a worldwide basis in and to any Program Know-How
developed or invented solely by employees of SEMBIOSYS and all Patent Rights
filed thereon.



     6.2.2 MARTEK Intellectual Property Rights.



     Subject only to the rights and obligations expressly provided in this
Agreement, MARTEK shall have sole and exclusive ownership of all right, title
and interest on a worldwide basis in and to any Program Know-How developed or
invented solely by employees of MARTEK and all Patent Rights filed thereon.



     6.2.3 Joint Intellectual Property Rights.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




24









 








     Subject only to the rights and obligations expressly provided in this
Agreement, MARTEK and SEMBIOSYS shall jointly own all Program Know-How jointly
developed or invented by employees of both SEMBIOSYS and MARTEK and all Patent
Rights filed thereon, with each party having full rights to use and disclose
such information and to grant licenses thereunder throughout the Territory.



     6.2.4 Rights in Improvements.



     Notwithstanding Sections 6.2.1 – 6.2.3, subject only to any obligations of
the parties pursuant to Article 8 and/or Article 9 of this Agreement, MARTEK
shall have an exclusive, perpetual, fully-paid (except as set forth in Sections
8.4.1 and 8.4.7) license to all Inventions and other Program Know-How owned in
whole or in part by SEMBIOSYS which are MARTEK Improvements, and SEMBIOSYS
shall have an exclusive, perpetual, fully-paid license to all Inventions and
other Program Know-How owned in whole or in part by MARTEK which are SEMBIOSYS
Improvements. In addition, each party shall have a perpetual, fully-paid
non-exclusive license to all unpatented Program Know-How owned by the other
party which is not included in the exclusive licenses granted above, but which
is reasonably necessary to practice such exclusive licenses.



     6.3 Patent Coordinators.



     SEMBIOSYS and MARTEK shall each appoint a patent coordinator (a “Patent
Coordinator”) who shall serve as such party’s primary liaison with the other
party on matters relating to patent filing, prosecution, maintenance and
enforcement. Each party may replace its Patent Coordinator at any time by
notice in writing to the other party. The initial Patent Coordinators shall be
designated by the parties upon execution of this Agreement.



     6.4 Inventorship.



     In case of dispute between SEMBIOSYS and MARTEK over inventorship or
authorship, the RSC, with the advice of the Patent Coordinators and counsel,
shall, at its next meeting, or as


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




25









 







soon as reasonably possible thereafter, following the disclosure of any
Invention pursuant to Section 6.1, make a determination of the inventor(s) or
author(s) by application of the standards embodied in United States patent and
copyright law. The RSC, with the advice of the Patent Coordinators and
counsel, shall also, in the case of dispute, make any determination as to
whether an invention is a MARTEK Improvement or a SEMBIOSYS Improvement.




7. PROVISIONS CONCERNING THE FILING, PROSECUTION,

MAINTENANCE AND ENFORCEMENT OF PATENT RIGHTS




     7.1 Filing of Patents.



     7.1.1 Primary Responsibilities.



     (a) MARTEK shall determine what Patent Rights will be filed in the
Territory on Inventions which are MARTEK Improvements. MARTEK shall also
determine what Patent Rights will be filed in the Territory on MARTEK
Inventions (other than SEMBIOSYS Improvements). MARTEK and SEMBIOSYS will
reasonably cooperate with each other to allow MARTEK to file and prosecute
patent applications relating to MARTEK Inventions (other than SEMBIOSYS
Improvements) and MARTEK Improvements.



     (b) SEMBIOSYS shall determine what Patent Rights will be filed in the
Territory on Inventions which are SEMBIOSYS Improvements. SEMBIOSYS shall also
determine what Patent Rights will be filed in the Territory on SEMBIOSYS
Inventions (other than MARTEK Improvements). MARTEK and SEMBIOSYS will
reasonably cooperate with each other to allow SEMBIOSYS to file and prosecute
patent applications relating to SEMBIOSYS Inventions (other than MARTEK
Improvements) and SEMBIOSYS Improvements.



     (c) The parties will mutually agree on the filing and prosecution of any
Patent Rights on Joint Inventions which are not SEMBIOSYS Improvements or
MARTEK Improvements and shall share the costs associated with such patent
filing and prosecution as mutually agreed.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




26









 







     (d) Responsibility for Patent Rights as described above shall include
responsibility for the filing, prosecution and maintenance (including the
defense of interferences and similar proceedings) of any such Patent Rights.




     7.1.2 Elective Termination of Rights.



     If at any time SEMBIOSYS wishes to discontinue the prosecution or
maintenance of any Patent Rights filed by it in accordance with Section 7.1.1
which are relevant to the Field, SEMBIOSYS shall promptly give notice of such
intention to MARTEK together with the reasons for such decision. In the event
that SEMBIOSYS’ decision is not based upon considerations of double-patenting,
lack of patentability, or potential interference, then MARTEK shall have the
right, but not the obligation, to assume responsibility for the prosecution of
any such Patent Rights at its own expense and in the name of SEMBIOSYS, by
giving notice to SEMBIOSYS of such intention within thirty (30) days and MARTEK
shall thereafter have a perpetual fully-paid license under such SEMBIOSYS
Patent Right for use in the Field. MARTEK shall thereafter keep SEMBIOSYS
reasonably informed as to the status of the prosecution, issuance and
maintenance of any such patent or patent application.



     7.2 Expenses.



     Each party will bear the costs of the filing, prosecution and maintenance
of all Patent Rights for which it has responsibilities pursuant to Section 7.1.



     7.3 Legal Action.



     7.3.1 Actual or Threatened Infringement.



          (a) In the event either party becomes aware of any possible infringement
or unauthorized possession, knowledge or use of any Patent Rights or Program
Know-How licensed hereunder (collectively, an “Infringement”), that party shall
promptly notify the other party and


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




27









 







provide it with full details. The parties will meet to determine the
appropriate course of action, and will collaborate in pursuing such course of
action.




          (b) Notwithstanding the foregoing, if the parties do not otherwise agree
on a course of action, MARTEK shall have primary responsibility for the
prosecution, prevention or termination of any Infringement in the Field at
MARTEK’s expense and with the sharing of recoveries as specified below. If
MARTEK does not commence an action on its own to prosecute, or otherwise take
steps to prevent or terminate, an Infringement of any Patent Right for which
SEMBIOSYS has primary responsibility pursuant to Section 7.1, the parties may
agree to jointly pursue an action, or if no such joint action is pursued within
ninety (90) days of any written request of SEMBIOSYS, then SEMBIOSYS shall have
the right and option to take such reasonable action as it considers appropriate
to prosecute, prevent or terminate such Infringement. If either party
determines that it is necessary or desirable for the other to join any such
suit, action or proceeding, the second party shall execute all papers and
perform such other acts as may be reasonably required in the circumstances.



          (c) MARTEK shall bear the cost of any proceeding or suit under Section
7.3.1(b) brought by MARTEK and SEMBIOSYS shall bear the cost of any proceeding
or suit under Section 7.3.1(b) brought by SEMBIOSYS (for the purposes of this
Section each hereafter a “responsible party”). In each such case, the
responsible party shall have the right first to reimburse itself out of any
sums recovered in such suit or in its settlement for all reasonable costs and
expenses, including reasonable attorney’s fees, related to such suit or
settlement. The remainder is next to be used to reimburse the other party for
its costs and expenses so incurred. Any remaining amounts shall be shared as
follows: 90% to the responsible party and 10% to the other party. Any
non-monetary recovery or award shall be shared as mutually agreed between the
parties hereto. The parties shall jointly bear the cost of any joint action
under Section 7.3.1(b) and shall share equally in any recovery. Each party
shall always have the right to be represented by counsel of its own selection
and at its own expense in any suit instituted under this Section by the other
party for an Infringement. If either party lacks standing and the other


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




28









 







party has standing to bring any such suit, action or proceeding as
specified above, then the other party shall do so at the request of the
responsible party and at the responsible party’s expense.




          (d) For Infringements outside the Field, the party owning or controlling
the relevant Patent Rights or Program Know-How as provided in Section 6.2 shall
have the right to pursue infringers, and the parties shall jointly agree on any
enforcement of Joint Program Intellectual Property outside the Field.



          (e) In any action under this Section 7.3.1, the parties shall fully
cooperate with and assist each other. No suit under Section 7.3.1 regarding
SEMBIOSYS Patent Rights or Joint Patent Rights may be settled or compromised by
MARTEK without SEMBIOSYS’ consent. No suit under Section 7.3.1 regarding
MARTEK Patent Rights or Joint Patent Rights may be settled or compromised by
SEMBIOSYS without MARTEK’s consent.



     7.3.2 Defense of Claims Asserted by Third Parties.



     Notwithstanding anything to the contrary in this Agreement, in the event
that any action, suit or proceeding is brought against SEMBIOSYS or any
Affiliate of SEMBIOSYS or MARTEK or any Affiliate, licensee or sublicensee of
MARTEK alleging the infringement of the intellectual property rights of a Third
Party by reason of the discovery, development, manufacture, use, sale,
importation or offer for sale of a Licensed Product by MARTEK or its
Affiliates, licensees or sublicensees, MARTEK will have the obligation to
defend itself and SEMBIOSYS and such Affiliate, licensee or sublicensee in such
action, suit or proceeding at MARTEK’s expense, except if the action, suit or
proceeding is brought primarily due to the actions of SEMBIOSYS in its
development of transgenic plants, including but not limited to the use of
SEMBIOSYS’ proprietary technologies (in which case, MARTEK shall have no
obligation to defend SEMBIOSYS hereunder). SEMBIOSYS shall have the right to
separate counsel at its own expense in any such action or proceeding and MARTEK
will reimburse SEMBIOSYS for all reasonable expenditures incurred in connection
therewith. The parties will cooperate with each other in the defense of any
such suit, action or proceeding. The parties will


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




29









 







give each other prompt written notice of the commencement of any such
suit, action or proceeding or claim of infringement and will furnish each other
a copy of each communication relating to the alleged infringement. MARTEK
shall not compromise, litigate, settle or otherwise dispose of any such suit,
action or proceeding which involves SEMBIOSYS Program Intellectual Property or
Joint Program Intellectual Property without SEMBIOSYS’ advice and prior
consent, provided that SEMBIOSYS shall not unreasonably withhold its consent to
any settlement which does not have a material adverse effect on SEMBIOSYS or
SEMBIOSYS’ business.




8. LICENSE RIGHTS




     8.1 License Grants.



     8.1.1 Research Licenses



     (a) Subject to the terms and conditions of this Agreement, during the
Research Term, MARTEK hereby grants to SEMBIOSYS a fully-paid up,
non-exclusive, royalty-free, worldwide license, without the right to grant
sublicenses, under MARTEK Background Technology, MARTEK Program Intellectual
Property (including MARTEK Improvements), and MARTEK’s interest in Joint
Program Intellectual Property, for the sole purpose of conducting the
activities required in the performance of its obligations hereunder as part of
the R&D Program.



     (b) Subject to the terms and conditions of this Agreement, during the
Research Term, SEMBIOSYS hereby grants to MARTEK a fully-paid up,
non-exclusive, royalty-free, worldwide license, without the right to grant
sublicenses, under SEMBIOSYS Background Technology, SEMBIOSYS Program
Intellectual Property (including SEMBIOSYS Improvements), SEMBIOSYS’ interest
in Joint Program Intellectual Property, and any relevant Third Party Licenses,
for the sole purpose of conducting the activities required in the performance
of its obligations hereunder as part of the R&D Program.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




30









 







     8.1.2 Commercialization License.




     (a) Subject to the terms and conditions of this Agreement, SEMBIOSYS
hereby grants to MARTEK a sole and exclusive license in the Territory to make,
have made, use, have used, import, have imported, offer for sale, sell and have
sold Licensed Products in the Field, with rights to grant sublicenses that are
co-extensive with such license, under any and all SEMBIOSYS Program
Intellectual Property (including SEMBIOSYS Improvements), and SEMBIOSYS’ rights
in Joint Program Intellectual Property. MARTEK shall have the right to assign
or otherwise transfer its rights in the license granted herein (or any part
thereof) to its Affiliates. Notwithstanding any such assignment, MARTEK shall
be responsible for the activities, including all reporting and royalty
obligations, of such Affiliates as if they were MARTEK.



     (b) Subject to the terms and conditions of this Agreement, SEMBIOSYS
hereby grants to MARTEK a sole and exclusive license in the Territory to make,
have made, use, have used, import, have imported, offer for sale, sell and have
sold Licensed Products in the Field solely as it relates to DHA, with rights to
grant sublicenses that are co-extensive with such license, under any and all
SEMBIOSYS Background Technology. MARTEK shall have the right to assign or
otherwise transfer its rights in the license granted herein (or any part
thereof) to its Affiliates. Notwithstanding any such assignment, MARTEK shall
be responsible for the activities, including all reporting and royalty
obligations, of such Affiliates as if they were MARTEK.



     (c) Subject to the terms and conditions of this Agreement and the specific
limitations set forth in Section 8.1.2(d), SEMBIOSYS hereby grants to MARTEK an
exclusive sublicense in the Territory under the Third Party Licenses solely to
the extent necessary to allow MARTEK to practice the licenses granted in
subsections (a) and (b) above as they relate to DHA. MARTEK shall not have the
right to assign or otherwise transfer its rights in the license granted herein
(or any part thereof) without the prior written consent of SEMBIOSYS, which
consent shall not be


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




31









 







unreasonably withheld. SemBioSys shall cooperate with Martek in good
faith to secure any rights for Martek under such Third Party Licenses directly
from the relevant licensors upon the occurrence of the relevant events, and on
the terms and conditions, in each case as expressly provided in the relevant
Third Party License.




     (d) Notwithstanding subsection (c) above, MARTEK shall have no right under
the Third Party Licenses to make or have made transgenic plants capable of
producing DHA or to propagate or have propagated any transgenic plant material
capable of producing DHA or produce seed of transgenic plants capable of
producing DHA until the expiration of all relevant patents licensed to
SEMBIOSYS under the Third Party Licenses except as otherwise expressly provided
in any such Third Party License as in effect on the Effective Date. Prior to
the patent expiration of all relevant patents licensed to SEMBIOSYS under the
Third Party Licenses, SEMBIOSYS shall propagate plant material and/or produce
seed from transgenic plants producing DHA as an exclusive contract manufacturer
for MARTEK pursuant to a Supply Agreement to be negotiated in good faith by the
parties and agreed to prior to the first anniversary of the Effective Date.
Such Supply Agreement shall specify that material to be provided for use in the
R&D Program shall be paid for as an R&D Program cost in accordance with Section
4.2 hereof and that material to be provided for use in commercialization of DHA
shall be paid for at a cost that includes reasonable manufacturing margins
provided that such cost shall not be greater than the cost to MARTEK should it
have the right to propagate the transgenic plant material itself.
Notwithstanding the foregoing, in the event that at any time during the term of
the Supply Agreement SEMBIOSYS and/or its existing subcontractors are unable to
propagate plant material and/or produce seed from transgenic plants producing
DHA as an exclusive contract manufacturer for MARTEK, SEMBIOSYS agrees that, at
MARTEK’s request, it will subcontract propagation of relevant plant material
and/or the production of relevant transgenic plants and/or seeds in accordance
with the Third Party Licenses, to MARTEK and/or MARTEK’s qualified designees.
In the event that material generated through such subcontracting activities is
transferred to or from SEMBIOSYS as part of the


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




32









 







subcontracting activities pursuant to the foregoing sentence, SEMBIOSYS
agrees that it will only charge MARTEK the direct costs associated with any
such transfer.




     8.1.3 No Other Rights.



     Neither party shall receive any rights to utilize any proprietary rights
owned or controlled by the other party except as expressly set forth herein.



     8.2 Term of Commercialization License.



     The “License Term” with respect to any rights licensed to MARTEK in
Section 6.2.4 and 8.1.2 for any Licensed Product shall commence upon the
Effective Date and shall continue on a country-by-country basis until the later
of (a) sixteen (16) years (or such shorter period as required by law) following
commercial launch in such country or (b) expiration of the last to expire
Patent Rights licensed to MARTEK pursuant to this Agreement claiming such
Licensed Product. Thereafter, MARTEK shall have a fully paid-up license of
perpetual duration to all SEMBIOSYS Background Technology, all SEMBIOSYS
Program Intellectual Property, and SEMBIOSYS’ interest in all Joint Program
Intellectual Property with respect to such Licensed Product.



     8.3 Licenses and Sublicenses to Third Parties.



     If MARTEK grants a license or sublicense as permitted herein to a Third
Party with respect to any SEMBIOSYS Background Technology, SEMBIOSYS Program
Intellectual Property, and/or Joint Program Intellectual Property, MARTEK shall
guarantee that such licensee or sublicensee will fulfill all of MARTEK’s
obligations under this Agreement; provided, however, that MARTEK shall remain
directly liable for the fulfillment of all such obligations unless otherwise
consented to in writing by SEMBIOSYS.



     8.4 Payment of Royalties, Accounting for Royalties and Records.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




33









 







     8.4.1 Royalties on Sales of DHA.




     In consideration of the licenses granted to MARTEK pursuant to this
Agreement with respect to DHA, MARTEK shall pay to SEMBIOSYS a royalty as
determined below on sales of Licensed Products equal to * of (i) the Gross
Margin realized by MARTEK on the sales of such Licensed Products by MARTEK or
its Affiliates, and (ii) any royalties or other license income received during
the License Term by MARTEK as consideration for a license or sublicense of
Licensed Products. Notwithstanding any other provision hereof, all sales of
Licensed Products to distributors, whether or not made with restrictions as to
use or resale, shall be deemed sales by MARTEK and not licenses of Licensed
Products for purposes of the foregoing.



     The royalty rate shall vary * depending on (a) the Development
Contribution as set forth in the table below as determined based on the stage
of development of the Licensed Product at the time of any termination of the
R&D Program and this Agreement (if such termination occurs) and/or completion
of Phase IV of the R&D Program, and (b) the level of DHA in the resulting
commercial crop (“the DHA Royalty Contribution”). The Development Contribution
and the DHA Royalty Contribution will be determined in accordance with the
following tables:



I. DEVELOPMENT CONTRIBUTION TABLE




	 	 	 
	Status at Termination or	 	 
	Completion	 	Development Contribution
	Phase I: Model System POC

	*

	 	*
	*

	 	*
	*

	 	*
	Phase II: Commercial Crop POC

	*

	 	*
	*

	 	*






*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




34









 








	 	 	 
	*

	 	*
	Phase III: Crop Product Optimization

	*

	 	*
	Phase IV: Regulatory Clearance and Commercialization

	*

	 	*







II. DHA ROYALTY CONTRIBUTION TABLE




	 	 	 
	% DHA in Commercial Crop#	 	DHA Royalty Contribution
	*
	 	 
	*

	 	*
	*

	 	*
	*

	 	*
	*

	 	*
	*

	 	*
	*

	 	*
	*

	 	*







# The percentage of DHA in the commercial crop will be the
average percentage of DHA in the crop for a given growing season.
When a range is specified in either table, the contribution is
directly proportional to the level of DHA actually achieved.



     The effective royalty rate will be calculated as follows: Development
Contribution multiplied by DHA Royalty Contribution. Notwithstanding the
foregoing, provided that upon completion of Phase I, POC in * has been achieved
with a yield of at least *, the minimum royalty rate payable to SEMBIOSYS
hereunder shall be *.



     8.4.2 Example.



     As an example of the calculations to be performed pursuant to Section
8.4.1 above,


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




35









 







     1. If the R&D Program is terminated during or after Phase I with
achievement of an * plant containing * and the level of DHA in the commercial
crop is *, the royalty rate will be *.




     2. If the R&D Program is terminated during or after Phase II with
achievement of a * plant containing * and the level of DHA in the commercial
crop is *, the royalty rate will be *.



     3. If the R&D Program is terminated after Phase III with achievement of a
commercial * plant containing * and the level of DHA in the commercial crop is
*, the royalty rate will be *.



     4. If the R&D Program is successfully completed through Phase IV and the
level of DHA in the commercial crop is *, the royalty rate will be *.



     8.4.3 Payment Dates and Reports.



     Royalties shall be paid by MARTEK within sixty (60) days after the end of
each Calendar Quarter in any Calendar Year in which sale of Licensed Products
occurs. Such payments shall be accompanied by a report showing the quantity of
Licensed Product sold, the applicable royalty rate for such Licensed Product,
the aggregate Gross Margin for the quantity of Licensed Products sold, an
accounting for licensing income if relevant, and the amount of royalty due.



     8.4.4 Accounting.



     The Gross Margin used for computing the royalties payable to SEMBIOSYS
hereunder shall be computed, and royalties shall be paid, in U.S. dollars. For
purposes of determining the amount of royalties due, the amount of sales or
revenues in any foreign currency shall be computed by converting such amount
into U.S. dollars at the prevailing commercial rate of


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




36









 







exchange for purchasing dollars with such foreign currency as reported in
The Wall Street Journal on the last business day of the period to which
a royalty payment relates.




     8.4.5 Records.



     MARTEK, its Affiliates, licensees and sublicensees shall keep for three
(3) years from the date of each payment of royalties complete and accurate
records of sales by MARTEK and its Affiliates, licensees and sublicensees of
each Licensed Product as well as cost of sales, licensing income and percentage
DHA calculations in sufficient detail to allow the accruing royalties to be
determined accurately. SEMBIOSYS shall have the right for a period of three
(3) years after receiving any report or statement with respect to royalties due
and payable to appoint an independent certified public accountant reasonably
acceptable to MARTEK to inspect the relevant records of MARTEK and its
Affiliates, licensees and sublicensees to verify such report or statement.
MARTEK and its Affiliates, licensees and sublicensees shall make its records
available for inspection by such independent certified public accountant during
regular business hours at such place or places where such records are
customarily kept, upon reasonable notice from SEMBIOSYS, solely to verify the
accuracy of the reports and payments. Such inspection right shall not be
exercised more than once in any Calendar Year nor more than once with respect
to sales of any Licensed Product in any given Calendar Quarter. SEMBIOSYS
agrees to hold in strict confidence all information concerning royalty payments
and reports, and all information learned in the course of any audit or
inspection, except to the extent necessary for SEMBIOSYS to reveal such
information in order to enforce its rights under this Agreement or if
disclosure is required by law, regulation or judicial order. SEMBIOSYS shall
pay for such inspections, except that in the event there is any upward
adjustment in aggregate royalties payable for any Calendar Year of the
inspected party shown by such inspection of more than five percent (5%) of the
amount paid, MARTEK shall pay for such inspection.



     8.4.6 Overdue Royalties.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




37









 







     Royalties not paid within the time period set forth in Section 8.4.3 shall
bear interest at a rate of one percent (1%) per month from the due date until
paid in full.




     8.4.7 Royalties on ARA and EPA.



     Unless otherwise provided in any agreement entered into pursuant to
Section 3.1.1, in the event that MARTEK develops an ARA or EPA product in the
Field which is a Licensed Product, MARTEK and SEMBIOSYS shall negotiate in good
faith an appropriate royalty within a range from * of the Gross Margin on sales
of such a Licensed Product which shall take into account the contributions of
SEMBIOSYS to the development of any such Licensed Product using a structure
similar to that set forth in Section 8.4.1. Such royalty shall be negotiated
upon request of MARTEK, but in any event prior to the first introduction of a
nucleic acid construct relating to EPA or ARA metabolism into a commercial crop
which is a Licensed Product. MARTEK’s obligations and SEMBIOSYS’ rights set
forth in Sections 8.4.3, 8.4.4, 8.4.5, and 8.4.6 shall apply to all sales of
any such Licensed Products containing ARA or EPA. Nothing in this Section
8.4.7 shall affect any royalties payable pursuant to Section 8.4.1 above with
respect to sales of Licensed Products containing DHA. Any royalty for an ARA
or EPA product negotiated pursuant to this Section 8.4.7 shall be structured to
include tables similar to those tables set out in Section 8.4.1 (I) and (II)
above, but with different percentages and different factors used to determine
when each such percentage applies.



     8.5 Commercialization Efforts.



     MARTEK agrees that it will use commercially reasonable efforts to develop
and market Licensed Products in the Field throughout the Territory at its own
expense, but only to the extent that the development and commercialization of
such Licensed Products is economically practicable and the market for such
Licensed Products justifies, in MARTEK’s sole discretion, such development and
sale.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission




38









 








9. TERMINATION AND DISENGAGEMENT




     9.1 Term of Agreement.



     The term of this Agreement (“Term”) shall commence on the Effective Date
and shall continue until the expiration of the License Term or until this
Agreement expires or is terminated pursuant to Section 2.3 hereof or this
Article 9, whichever shall first occur.



     9.2 Discretionary Termination.



     MARTEK may terminate this Agreement at its sole discretion after the
successful completion of Phase IV of the R&D Program upon six (6) months prior
written notice.



     9.3 Material Breach.



     This Agreement may be terminated by either party upon written notice
following any material breach of this Agreement by the other party as described
below.



          (a) A material breach of this Agreement by a party shall occur:




     (i) upon the failure of such party to pay, when due, any
amount due hereunder to the other party, in which event termination
shall be effective sixty (60) days after receiving written notice
from the other party of such failure to pay; or




     (ii) upon material breach of any other material obligation or
condition by such party, in which event termination shall be
effective ninety (90) days after receiving written notice from the
other party of such breach.


*The asterisk denotes that confidential portions of this exhibit have been
omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The
confidential portions have been submitted separately to the Securities and
Exchange Commission





39










 







          (b) The foregoing notwithstanding, if the default or breach is cured,
remedied or shown to be non-existent within the aforesaid sixty (60) or ninety
(90) day period, the notice shall be deemed automatically withdrawn and of no
effect.



     9.4 Change of Control.



     This Agreement may be terminated by MARTEK upon written notice to
SEMBIOSYS following any Change of Control of SEMBIOSYS. SEMBIOSYS shall
promptly notify MARTEK of any Change of Control.



     9.5 Termination Upon Bankruptcy.



          (a) If either party is dissolved or liquidated, files for protection under
bankruptcy laws, makes an assignment for the benefit of creditors, appoints or
suffers appointment of a receiver or trustee over its property, files a
petition under any bankruptcy or insolvency act or has any such petition filed
against it which is not discharged within sixty (60) days of the filing
thereof, then the other party may terminate this Agreement by notice to such
party.



          (b) All rights and licenses granted under or pursuant to this Agreement by
SEMBIOSYS to MARTEK, and by MARTEK to SEMBIOSYS, are, and shall otherwise be
deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code,
licenses or rights to “intellectual property” as defined under Section 101(52)
of the U.S. Bankruptcy Code. The parties agree that each party, as a licensee
of such rights under this Agreement, shall retain and may fully exercise all of
its rights and elections under the U.S. Bankruptcy Code, subject to performance
by the licensee of its preexisting obligations under this Agreement. The
parties further agree that, in the event of the commencement of a bankruptcy
proceeding by or against the licensor under the U.S. Bankruptcy Code, the
licensee shall be entitled to a complete


*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




40









 





duplicate of (or complete access to, as appropriate) any such intellectual
property and all embodiments of such intellectual property, and same, if not
already in its possession, shall be promptly delivered to the licensee (a) upon
any such commencement of a bankruptcy proceeding upon written request therefor
by the licensee, unless the licensor elects to continue to perform all of its
obligations under this Agreement, or (b) if not delivered under (a) above, upon
the rejection of this Agreement by or on behalf of the licensor upon written
request therefor by the licensee, provided, however, that upon the licensor’s
(or its successor’s) written notification to the licensee that it is again
willing and able to perform all of its obligations under this Agreement, the
licensee shall promptly return all such tangible materials to the licensor, but
only to the extent that the licensee does not require continued access to such
materials to enable the licensee to perform its obligations under this
Agreement.



     9.6 Effect of Termination.



     9.6.1 Continued Licenses Upon Qualifying Termination.



     (a) In the event of any expiration or termination of the Research Term
and/or the Agreement pursuant to Sections 2.3 or 9.4, or in the event of any
termination of the Agreement by MARTEK pursuant to Section 9.3 or 9.5 (any of
the foregoing, a “Qualifying Termination”), the licenses granted to MARTEK in
Section 8.1.2 shall continue for the License Term subject to the terms and
conditions set forth below and in Section 8.1.2.



Such license shall be: (A) non-exclusive if MARTEK terminates the Research Term
and this Agreement pursuant to Section 2.3.3(b) or if either party terminates
the Research Term and this Agreement pursuant to Section 2.3.3(c), or if MARTEK
terminates this Agreement pursuant to Section 9.4 where the merging or
acquiring entity is not a Material Competitor, in each case with royalties
equal to 75% of those provided in Section 8.4.1 hereof, and (B) exclusive, and
with royalties at the royalty rates stated in Section 8.4.1 hereof, in the
event of expiration of the Research Term under Sections 2.3.1 or 2.3.2,
termination of the Research Term under Section 2.3.3(a), termination of the
Agreement by MARTEK pursuant to Section 9.3 or 9.5, or

*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




41









 








termination of the Agreement by MARTEK pursuant to Section 9.4 where the
merging or acquiring entity is a Material Competitor.



     (b) Notwithstanding anything to the contrary in the foregoing subsection
(a), in the event of termination pursuant to Section 2.3.3(b) following the
successful and timely completion of Phase I of the R&D Program, MARTEK may (I)
elect to retain the aforementioned non-exclusive license, with royalties equal
to 75% of those provided in Section 8.4.1, and MARTEK shall also pay a program
termination fee of US$500,000, (II) elect to retain an exclusive license at the
full royalty rates stated in Section 8.4.1 and MARTEK shall pay a program
termination fee of US$1,000,000, or (III) elect to abandon the R&D Program and
terminate the Research Term, retain no continuing licenses under Section 8.1.2
and pay no program termination fee.



     (c) Any licenses to be continued as set forth in any sentence of Section
9.6.1(a) or (b) shall include the right to grant sublicenses, shall require the
payment of royalties for the duration of the License Term as defined in Section
8.2 above, and shall be terminable for breach or bankruptcy.



     (d) In the event of any termination of the Agreement by SEMBIOSYS pursuant
to Section 9.3 or 9.5 above, the R&D Program, the Research Term, and this
Agreement shall be automatically terminated and the licenses granted to MARTEK
under Sections 8.1.1 and 8.1.2 shall immediately terminate.



     (e) In the event of any termination of the Agreement by MARTEK pursuant to
Section 9.2 above, MARTEK shall have no right to any continuing licenses under
Section 8.1.2.



     (f) Upon any Qualifying Termination, MARTEK will be provided with a final
written report of all research conducted by SEMBIOSYS pursuant to the R&D
Program and, except in the event of an election by MARTEK under Section
9.6.1(b) (III) above, MARTEK shall have access to all work product and reports
necessary or useful in allowing MARTEK to continue the R&D Program alone or in
conjunction with a Third Party.

*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




42









 





     (g) For the purposes of clarity, the license granted by SEMBIOSYS to
MARTEK in Section 6.2.4 shall survive termination of this Agreement for any
reason and shall remain subject to the payment of royalties in accordance with
Sections 8.4.1 and 8.4.7.



     9.6.2 Other Consequences of Termination.



     Except with respect to any surviving rights and obligations as expressly
provided in this Article 9, upon any termination of this Agreement, all rights
and licenses granted hereunder shall terminate and each party shall return to
the other party all of the other party’s Confidential Information (other than
with respect to maintaining one (1) archival copy of such Confidential
Information related thereto for its legal files, for the sole purpose of
determining its obligations under this Agreement) and proprietary materials of
the other party in its possession, in each case unless included in, or
necessary to practice, any rights which survive such termination, and each
party shall provide the other party with certification by an officer of such
party that all such Confidential Information and proprietary materials have
been destroyed or returned to the other party, as appropriate.



     9.7 Surviving Provisions.



     Expiration or termination of this Agreement for any reason shall be
without prejudice to:



          (a) the rights and obligations of the parties provided in Article 5,
Sections 6.1, 6.2, 6.4, 7.1.1, 7.2, 8.1.3, 8.4, 9.6, 9.7, 10.1, 10.2, and
Articles 11, 12 and 13, all of which shall survive such termination;



          (b) the rights and obligations of the parties provided in Sections 7.1.2,
7.3, 8.2, 8.3 and 8.5 which shall survive such termination only for so long as
the licenses granted in Section 8.1.2, as they may be continued under Section
9.6.1(a) or (b), are in effect;



          (c) SEMBIOSYS’ right to receive all payments earned and/or accrued prior
to expiration or termination hereunder; and

*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




43









 





          (d) any other rights or remedies which either party may otherwise have
against the other.



10. REPRESENTATIONS AND WARRANTIES




     10.1 Mutual Representations.



     SEMBIOSYS and MARTEK each represents and warrants as follows:



     10.1.1 Organization.



     It is a corporation duly organized, validly existing and is in good
standing under the laws of its jurisdiction of incorporation, is qualified to
do business and is in good standing as a foreign corporation in each
jurisdiction in which the performance of its obligations hereunder requires
such qualification and has all requisite power and authority, corporate or
otherwise, to conduct its business as now being conducted, to own, lease and
operate its properties and to execute, deliver and perform this Agreement.



     10.1.2 Authorization.



     The execution, delivery and performance by it of this Agreement have been
duly authorized by all necessary corporate action and do not and will not (a)
require any consent or approval of its stockholders or (b) violate any
provision of any law, rule, regulation, order, writ, judgment, injunction,
decree, determination or award presently in effect having applicability to it
or any provision of its charter documents.



     10.1.3 Binding Agreement.



     This Agreement is a legal, valid and binding obligation of it enforceable
against it in accordance with its terms and conditions.



     10.1.4 No Inconsistent Obligation.

*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




44









 





     It is not under any obligation to any person, or entity, contractual or
otherwise, that is conflicting or inconsistent in any respect with the terms of
this Agreement or that would impede the diligent and complete fulfillment of

its obligations hereunder.



     10.1.5 Warranty Disclaimer.



     EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY
MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR
OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH
RESPECT TO ANY AND ALL OF THE FOREGOING.



     10.1.6 Limited Liability.



     NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR OTHERWISE, NEITHER
SEMBIOSYS NOR MARTEK WILL BE LIABLE WITH RESPECT TO ANY SUBJECT MATTER OF THIS
AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR
EQUITABLE THEORY FOR (I) ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE
DAMAGES OR LOST PROFITS OR (II) COST OF PROCUREMENT OF SUBSTITUTE GOODS,
TECHNOLOGY OR SERVICES.



     10.2 SEMBIOSYS Representations and Warranties.



     10.2.1 Third Party Licenses.



          (a) SEMBIOSYS represents and warrants to MARTEK that (i) it has the right
under the Third Party Licenses to perform the R&D Program as set forth in the
Workplan attached hereto, and (ii) it has the right to grant to MARTEK
sublicenses of SEMBIOSYS’ rights


*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission



45









 





under any license agreements pertaining to patent rights listed on
Exhibit C attached hereto (“Third Party Licenses”) as provided in
Section 8.1.2 of this Agreement.



          (b) SEMBIOSYS represents and warrants to MARTEK that it has provided
MARTEK with a true and complete copy of all relevant provisions of each Third
Party License in existence as of the Effective Date, and that SEMBIOSYS shall
not voluntarily terminate any Third Party License or amend any Third Party
License in any manner which would adversely affect MARTEK without the prior
written approval of MARTEK. In addition, SEMBIOSYS represents and warrants
that it has rights as of * under the * Licensing Agreement *between *and *
dated * and the Commercial Agreement for * and * by * between* and * dated* as
recited in the copies provided to MARTEK on a confidential basis and that it
shall not voluntarily terminate either Other Agreement without the prior
written approval of MARTEK, which approval shall not be unreasonably withheld.
SEMBIOSYS represents and warrants that in the event of any notice of
termination to SEMBIOSYS under a Third Party License or Other Agreement on the
basis of an alleged breach of such Third Party License or Other Agreement by
SEMBIOSYS, SEMBIOSYS shall promptly inform MARTEK of such notice and shall
cooperate with MARTEK and undertake all reasonable steps to cure any alleged
breach giving rise to such notice of termination within the time period allowed
for cure as set forth in such Third Party License or Other Agreement, as
relevant.



          (c) SEMBIOSYS further represents and warrants that during Phase I of the
R&D Program it shall use its commercially reasonable efforts in good faith to
assist MARTEK in securing all necessary rights under the Third Party Licenses
to allow MARTEK to continue the R&D Program, alone or in conjunction with a
Third Party, and to develop and commercialize DHA produced in any resulting
transgenic plants, and to remove the restrictions of Section 8.1.2(d) on the
license set forth in Section 8.1.2(c), in each case in the event of any
Qualifying Termination of this Agreement.



     10.2.2 Financial Reports.

*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




46









 





     SEMBIOSYS hereby warrants that it shall make available to MARTEK, on a
confidential basis, its quarterly financial statements within sixty (60) days
of the end of each Calendar Quarter.



11. INDEMNIFICATION




     11.1 Indemnification of SEMBIOSYS by MARTEK.



     MARTEK shall indemnify, defend and hold harmless SEMBIOSYS, its Affiliates
and their respective directors, officers, employees, and agents and their
respective successors, heirs and assigns (the “SEMBIOSYS Indemnitees”), against
any liability, damage, loss or expense (including reasonable attorneys’ fees
and expenses of litigation) incurred by or imposed upon the SEMBIOSYS
Indemnitees, or any of them, in connection with any claims, suits, actions,
demands or judgments of third parties, including without limitation personal
injury and product liability matters (except in cases where such claims, suits,
actions, demands or judgments result from a willful material breach of this
Agreement, gross negligence or willful misconduct on the part of SEMBIOSYS)
arising directly out of any actions of MARTEK in the performance of the R&D
Program or arising out of the development, testing, production, manufacture,
promotion, import, sale or use by any person of any Licensed Product
manufactured or sold by MARTEK or by an Affiliate, licensee, sublicensee,
distributor or agent of MARTEK.



     11.2 Indemnification of MARTEK by SEMBIOSYS.



     SEMBIOSYS shall indemnify, defend and hold harmless MARTEK, its
Affiliates, Agents and their respective directors, officers, employees, and
agents and their respective successors, heirs and assigns (the “MARTEK
Indemnitees”), against any liability, damage, loss or expense (including
reasonable attorneys’ fees and expenses of litigation) incurred by or


*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission



47









 





imposed upon the MARTEK Indemnitees, or any one of them, in connection with any
claims, suits, actions, demands or judgments of third parties (except in cases
where such claims, suits, actions, demands or judgments result from a willful
material breach of this Agreement, gross negligence or willful misconduct on
the part of MARTEK) arising directly out of any actions of SEMBIOSYS in the
performance of the R&D Program.



     11.3 Conditions to Indemnification.



     A party seeking indemnification under this Article 11 (the “Indemnified
Party”) shall give prompt notice of the claim to the other party (the
“Indemnifying Party”) and, provided that the Indemnifying Party is not
contesting the indemnity obligation, shall permit the Indemnifying Party to
control any litigation relating to such claim and disposition of any such
claim, provided that the Indemnifying Party shall act reasonably and in good
faith with respect to all matters relating to the settlement or disposition of
any claim as the settlement or disposition relates to parties being indemnified
under this Article 11 and provided, further, that the
Indemnifying Party shall not settle or otherwise resolve any claim without
prior notice to the Indemnified Party and the consent of the Indemnified Party
(which consent shall not be unreasonably withheld, conditioned or delayed) if
such settlement involves anything other than the payment of money by the
Indemnifying Party. The Indemnified Party shall cooperate with the
Indemnifying Party in its defense of any claim for which indemnification is
sought under this Article 11 and shall have the right to be present in person
or through counsel at all legal proceedings giving rise to the right of
indemnification.



12. DISPUTE RESOLUTION




     12.1 Senior Officials.



     The parties recognize that a bona fide dispute as to certain matters may
from time to time arise during the term of this Agreement which relates to
either party’s rights and/or obligations hereunder. In the event of the
occurrence of such a dispute, either party may, by notice to the


*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission



48









 





other party, have such dispute referred to their respective Chief Executive
Officers or other senior officials designated by such persons, for attempted
resolution by good faith negotiations within thirty (30) days after such notice
is received.



     12.2 Arbitration.



     12.2.1 General.



     In the event of any dispute, difference or question arising between the
parties in connection with this Agreement, the construction thereof, or the
rights, duties or liabilities of either party, which dispute cannot be amicably
resolved by the good faith efforts of the persons designated under Section
12.1, then such dispute shall be resolved by binding arbitration as set forth
in Section 12.2.2 below.



     12.2.2 Arbitration.



     Binding arbitration shall be conducted in accordance with the Commercial
Arbitration Rules of the American Arbitration Association (the “AAA”). The
arbitration panel shall be composed of three arbitrators, one of whom shall be
chosen by MARTEK, one by SEMBIOSYS and the third by the two so chosen. If both
or either of MARTEK or SEMBIOSYS fails to choose an arbitrator or arbitrators
within fourteen (14) days after receiving notice of commencement of arbitration
or if the two arbitrators fail to choose a third arbitrator within fourteen
(14) days after their appointment, the then President of the New York office of
the AAA shall, upon the request of both or either of the parties to the
arbitration, appoint the arbitrator or arbitrators required to complete the
board or, if he shall decline or fail to do so, such arbitrator or arbitrators
shall be appointed by the New York office of the AAA.



          (a) Exchange of Proposals. Within ten (10) days of the appointment
of the full arbitration panel, the parties shall exchange documents setting
forth their final detailed proposals for resolution of the matter in dispute,
together with a brief or other written memorandum supporting the merits of
their final proposal. The arbitration panel shall promptly convene a

*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




49









 





hearing, at which time each party shall have an agreed upon time
to argue and present witnesses in support of its final proposal.



          (b) Selection of Final Proposal. The arbitration panel shall
select the proposal which most closely reflects a commercially reasonable
interpretation of the terms of this Agreement as the way to resolve the matter.
In making their selection, the arbitrators shall not modify the terms or
conditions of either party’s final proposal nor shall the arbitrators combine
provisions from both final proposals. In making their selection, the
arbitrators shall consider the terms and conditions of this Agreement, the
relative merits of the final proposals, and the written and oral arguments of
the parties. In the event the arbitrators seek the guidance of the law of any
jurisdiction, the laws of the State of Delaware, USA, shall govern.



          (c) Notification of Decision. The arbitrators shall make their
decision known to both parties as quickly as possible by delivering written
notice of their decision to both parties. The parties shall agree in writing
to comply with the proposal selected by the arbitration panel within five (5)
days of receipt of notice of such selection. The decision of the arbitrators
shall be final and binding on the parties, and specific performance may be
ordered by any court of competent jurisdiction.



          (d) Costs. The parties shall bear their own costs in preparing for
the arbitration. The costs of the arbitrators shall be equally divided between
the parties.



13. MISCELLANEOUS




     13.1 Payment Method.



     Each payment to SEMBIOSYS under Article 4 of this Agreement shall be paid
by MARTEK in Canadian currency by wire transfer of funds to an account of
SEMBIOSYS in accordance with instructions provided by SEMBIOSYS.



     13.2 Notices.

*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




50









 





     All notices shall be in writing mailed via certified mail, postage prepaid
and return receipt requested, or via courier providing evidence of delivery, in
each case addressed as follows, or to such other address as may be designated
by notice so given from time to time:



	 	 	 	 	 
	

	 	If to MARTEK:
	 	Martek Biosciences Corporation
	

	 	 	 	6480 Dobbin Road
	

	 	 	 	Columbia, MD 21045
	

	 	 	 	USA
	

	 	 	 	Attention: General Counsel
	 
	 	 	 	 
	

	 	With a copy to:
	 	Mintz, Levin, Cohn, Ferris,
	

	 	 	 	Glovsky and Popeo, P.C.
	

	 	 	 	One Financial Center
	

	 	 	 	Boston, MA 02111
	

	 	 	 	USA
	

	 	 	 	Attention: Sarah Shoaf Cabot, Esq.
	 
	 	 	 	 
	

	 	If to SEMBIOSYS:
	 	SemBioSys Genetics, Inc.
	

	 	 	 	110, 2985 – 23 Avenue N.E.
	

	 	 	 	Calgary, AB T1Y 7L3
	

	 	 	 	CANADA
	

	 	 	 	Attention: Manager of Intellectual Property
	 
	 	 	 	 
	

	 	With a copy to:
	 	Hale and Dorr LLP
	

	 	 	 	60 State Street
	

	 	 	 	Boston, MA 02109
	

	 	 	 	USA
	

	 	 	 	Attention: Gretchen A. Rice, Esq.
	 
	 	 	 	 
	

	 	If to the RSC :
	 	To the Project Managers at their respective
addresses furnished in writing to the parties.







     Except as otherwise expressly provided in this Agreement or agreed in
writing by both parties, any notice, communication or payment required to be
given or made shall be deemed given or made and effective (i) when delivered
personally; or (ii) when receipt is acknowledged if sent by overnight express
or mailed by certified mail.



     13.3 Governing Law and Jurisdiction.

*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




51









 





     This Agreement shall be governed by and construed in accordance with the
laws of the State of Delaware, U.S.A., without regard to the application of
principles of conflicts of law.



     13.4 Binding Effect.



     This Agreement shall be binding upon and inure to the benefit of the
parties and their respective legal representatives, successors and permitted
assigns.



     13.5 Headings.



     Section and subsection headings are inserted for convenience of reference
only and do not form a part of this Agreement.



     13.6 Counterparts.



     This Agreement may be executed simultaneously in two or more counterparts,
each of which shall be deemed an original.



     13.7 Amendment; Waiver.



     This Agreement may be amended, modified, superseded or canceled, and any
of the terms may be waived, only by a written instrument executed by each party
or, in the case of waiver, by the party or parties waiving compliance. The
delay or failure of any party at any time or times to require performance of
any provisions shall in no manner affect the rights at a later time to enforce
the same. No waiver by any party of any condition or of the breach of any term
contained in this Agreement, whether by conduct, or otherwise, in any one or
more instances, shall be deemed to be, or considered as, a further or
continuing waiver of any such condition or of the breach of such term or any
other term of this Agreement.



     13.8 No Third Party Beneficiaries.


*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission



52









 





     Except as set forth in Article 11, no Third Party, including any employee
of any party to this Agreement, shall have or acquire any rights by reason of
this Agreement.



     13.9 No Agency or Partnership.



     Nothing contained in this Agreement shall give either party the right to
bind the other, or be deemed to constitute the parties as agents for the other
or as partners with each other or any Third Party.



     13.10 Assignment and Successors.



     This Agreement may not be assigned by either party without the consent of
the other, which shall not be unreasonably withheld, except that each party
may, without such consent, assign this Agreement and the rights, obligations
and interests of such party, in whole or in part, to any of its Affiliates, to
any purchaser of all or substantially all of its assets in the line of business
to which this Agreement pertains or to any successor corporation resulting from
any merger or consolidation of such party with or into such corporations.



     13.11 Force Majeure.



     Neither MARTEK nor SEMBIOSYS shall be liable for failure of or delay in
performing obligations set forth in this Agreement, and neither shall be deemed
in breach of its obligations, if such failure or delay is due to natural
disasters or any causes beyond the reasonable control of MARTEK or SEMBIOSYS.
In event of such force majeure, the party affected thereby shall use reasonable
efforts to cure or overcome the same and resume performance of its obligations
hereunder.

*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




53









 





     13.12 Interpretation.



     The parties hereto acknowledge and agree that: (i) each party and its
counsel reviewed and negotiated the terms and provisions of this Agreement and
have contributed to its revision; (ii) the rule of construction to the effect
that any ambiguities are resolved against the drafting party shall not be
employed in the interpretation of this Agreement; and (iii) the terms and
provisions of this Agreement shall be construed fairly as to all parties hereto
and not in a favor of or against any party, regardless of which party was
generally responsible for the preparation of this Agreement.



     13.13 Integration: Severability.



     This Agreement is the sole agreement with respect to the subject matter
hereof and supersedes all other agreements and understandings between the
parties with respect to same, including but not limited to the Non-Disclosure
Agreement between SEMBIOSYS and MARTEK dated February 26, 2003 (the “Superseded
Confidentiality Agreement”). If any provision of this Agreement is or becomes
invalid or is ruled invalid by any court of competent jurisdiction or is deemed
unenforceable, it is the intention of the parties that the remainder of this
Agreement shall not be affected. The parties hereto covenant and agree to
renegotiate any such provision in good faith in order to provide a reasonably
acceptable alternative to any such provision that is invalid, illegal or
unenforceable, it being the intent of the parties that the basic purposes of
this Agreement are to be effectuated.



     13.14 Export Compliance.



     Each party and its Affiliates and sublicensees shall comply with all
United States laws and regulations controlling the export of certain
commodities and technical data, including without limitation all Export
Administration Regulations of the United States Department of Commerce. Among
other things, these laws and regulations prohibit or require a license for the
export of certain types of commodities and technical data to specified
countries. Each party


*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission



54









 





hereby gives written assurance that it will comply with, and will cause
its Affiliates and sublicensees to comply with, all United States export
control laws and regulations, that it bears sole responsibility for any
violation of such laws and regulations by itself or its Affiliates or
sublicensees, and that it will indemnify, defend, and hold the other party
harmless (in accordance with Article 11) for the consequences of any such
violation.



     13.15 Further Assurances.



     Each of MARTEK and SEMBIOSYS agrees to duly execute and deliver, or cause
to be duly executed and delivered, such further instruments and do and cause to
be done such further acts and things, including, without limitation, the filing
of such additional assignments, agreements, documents and instruments, that may
be necessary or as the other party hereto may at any time and from time to time
reasonably request in connection with this Agreement or to carry out more
effectively the provisions and purposes of, or to better assure and confirm
unto such other party its rights and remedies under, this Agreement.



[Remainder of page intentionally left blank]


*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




55









 








     IN WITNESS WHEREOF, the parties have caused this Agreement to be executed
by their duly authorized representatives.




	 	 	 
	

	 	MARTEK BIOSCIENCES CORPORATION
	 
	 	 
	

	 	By: /s/ Henry Linsert
Jr.         
	

	 	Name: Henry Linsert Jr.          
	

	 	Title: Chief Executive Officer 
	

	 	Date: 12/2/03       
        
           
	 
	 	 
	

	 	SEMBIOSYS GENETICS, INC.
	 
	 	 
	

	 	By: /s/ Andrew
Baum              
	

	 	Name: Andrew Baum          
    
	

	 	Title: Chief Executive Officer  
	

	 	Date: Dec 1, 2003 
                     





*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




56









 






EXHIBIT A




Martek R&D Program Workplan




All monetary amounts are stated in USD




	 	 	 	 	 	 	 
	Assumptions:
	 	* Allocation

	Project Value

	 	*
	 	Phase 1a
	 	*
	FTE (Cdn $)

	 	*
	 	Phase 1b
	 	*
	US Exchange Rate

	 	*
	 	Phase 2
	 	*
	US Adjusted FTE

	 	*
	 	Phase 3
	 	*
	

	 	 	 	Phase 4
	 	*







	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Budget Cap
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Cummulative	 	Cummulative	 	 	 	 	 	for
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	SemBioSys	 	 	 	 	 	Timeline	 	Timeline	 	 	 	 	 	Purposes of
	 	 	 	 	 	 	 	 	 	 	Duration	 	FTE /	 	 	 	 	 	Estimated	 	Timeline	 	(Months) w/o	 	(Months) w/	 	 	 	 	 	Calculating
	Phase
	 	Task
	 	FTE
	 	(Months)
	 	Task
	 	Notes
	 	Cost
	 	(Months)
	 	Phase Ib
	 	Phase Ib
	 	*
	 	* Payments






*


*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission



57









 






EXHIBIT B




Gross Margin Calculation




“Gross Margin” means, with respect to Licensed Products, Sales Revenue less
Cost of Goods Sold.



“Sales Revenue” means, with respect to Licensed Products, charges made to
customers for products sold net of returns, allowances, discounts, freight and
other similar items, and excluding sales taxes, in accordance with Generally
Accepted Accounting Principles (GAAP).



“Cost of Goods Sold” means, with respect to Licensed Products, all costs
directly related to the production and sale of the Licensed Products including
direct materials and labor as well as the application of indirect costs and
overhead related to the production of the Licensed Product, in accordance with
GAAP, including uncollectible customer payments.

*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




58









 








EXHIBIT C




Third Party Licenses





	1.	 	License Agreement between * and * effective as of *.
	 
	2.	 	License Agreement between * and * effective as of *.
	 
	3.	 	License Agreement between * and *.







*The asterisk denotes that confidential portions
of this exhibit have been omitted in reliance on Rule 24b-2 of
the Securities Exchange Act of 1934. The confidential portions have been submitted separately to
the Securities and Exchange Commission




59